Alasdair Muir Breckenridge

Alasdair Muir Breckenridge's AcademicInfluence.com Rankings

Medical

#1971

World Rank

#2359

Historical Rank

Pharmacology

#196

World Rank

#236

Historical Rank

medical Degrees

Alasdair Muir Breckenridge

Philosophy

#5796

World Rank

#8698

Historical Rank

Logic

#3013

World Rank

#4105

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Alasdair Muir Breckenridge Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alasdair Muir Breckenridge's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients (2004) (3053)
Meyler's Side Effects of Drugs (1976) (553)
CIMETIDINE: INTERACTION WITH ORAL ANTICOAGULANTS IN MAN (1979) (333)
Adverse drug reactions (1998) (323)
Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response (2011) (298)
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. (1974) (274)
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man (1974) (271)
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma (2008) (219)
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials (2009) (212)
May mothers given warfarin breast-feed their infants? (1977) (207)
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV‐infected patients (1997) (196)
Clinical Implications of Enzyme Induction and Enzyme Inhibition (1981) (177)
Clinical Pharmacokinetics of Oral Contraceptive Steroids (1983) (171)
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. (1991) (166)
Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. (1984) (158)
Pharmacokinetics of halofantrine in man: effects of food and dose size. (1989) (146)
Changes in Plasma γ-Glutamyl Transpeptidase Activity Associated with Alterations in Drug Metabolism in Man (1973) (127)
The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. (1980) (124)
An investigation of the pharmacokinetics of ethynylestsadiol in women using badioimmunoassay (1979) (120)
Overcoming the legal and regulatory barriers to drug repurposing (2018) (119)
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. (1988) (119)
The disposition of amodiaquine in man after oral administration. (1987) (119)
Prognosis of treated hypertension (1970) (118)
Open Clinical Trial Data for All? A View from Regulators (2012) (114)
PLACEBO-CONTROLLED COMPARISON OF CAPTOPRIL, ATENOLOL, LABETALOL, AND PINDOLOL IN HYPERTENSION COMPLICATED BY INTERMITTENT CLAUDICATION (1987) (109)
The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. (1981) (105)
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. (1988) (103)
Reporting of adverse drug reactions by nurses (2003) (102)
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. (1988) (102)
Clinical Pharmacokinetics of Anthelmintic Drugs (1988) (101)
The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. (1992) (96)
CLINICAL IMPLICATIONS OF ENZYME INDUCTION (1971) (94)
Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. (1985) (93)
The burden of alcohol misuse on an inner-city general hospital. (2000) (93)
The risks of risk aversion in drug regulation (2013) (91)
Mini-Sentinel and regulatory science--big data rendered fit and functional. (2014) (90)
Stereoselective interaction between the R enantiomer of warfarin and cimetidine. (1986) (89)
An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. (1992) (89)
The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. (1980) (88)
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis (2000) (88)
Therapy of Falciparum Malaria in Sub-Saharan Africa: from Molecule to Policy (2004) (85)
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. (1990) (85)
Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. (1991) (83)
The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. (1990) (83)
Oral anticoagulant drugs: pharmacokinetic aspects. (1978) (81)
Review of company postmarketing surveillance studies. (1992) (79)
The reproducibility of limb blood flow measurements in human volunteers at rest and after exercise by using mercury-in-Silastic strain gauge plethysmography under standardized conditions. (1986) (77)
The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. (1982) (74)
Kinetics of norethindrone in women; II. Single‐dose kinetics (1978) (73)
The disposition of amodiaquine in Zambians and Nigerians with malaria. (1990) (73)
Dose‐dependent enzyme induction (1973) (72)
Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. (1989) (72)
Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. (1984) (72)
The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution (2004) (71)
Kinetics of warfarin absorption in man (1973) (71)
Zidovudine phosphorylation in HIV‐infected patients and seronegative volunteers (1994) (69)
In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. (1990) (69)
The biliary and urinary metabolites of [3H]17α-ethynylestradiol in women (1983) (67)
New approaches to drug safety: a pharmacovigilance tool kit (2009) (67)
Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency (1996) (66)
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. (2010) (64)
Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. (1985) (63)
Lack of effect of ranitidine on warfarin action. (1981) (63)
Enantiomers of warfarin and vitamin K1 metabolism. (1986) (62)
Interactions of Benzodiazepines with Warfarin (1972) (62)
The effects of ampicillin on oral contraceptive steroids in women. (1982) (61)
A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. (1985) (60)
The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. (1991) (60)
Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. (1983) (59)
The effect of antibiotics on the enterohepatic circulation of ethinylestradiol and norethisterone in the rat. (1978) (59)
The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. (1972) (58)
Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. (1991) (57)
Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). (1971) (57)
Interaction of ethinyloestradiol with ascorbic acid in man. (1981) (56)
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. (1989) (56)
The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. (1992) (55)
Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. (1990) (55)
Poor medication adherence in clinical trials: consequences and solutions (2017) (55)
Drug protein conjugates--I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat. (1982) (54)
Interindividual differences in rates of drug oxidation in man. (1973) (53)
Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man (2004) (53)
In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs (1995) (52)
Drug-protein conjugates--XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. (1989) (51)
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine (1998) (50)
Reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat: correlation with changes in the gut flora. (1980) (49)
The Future of Drug Safety (2007) (48)
Effects of methyldopa on prolactin and growth hormone. (1976) (47)
Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. (1992) (46)
Kinetics of norethindrone in women; I. Radioimmunoassay and concentrations during multiple dosing (1978) (45)
High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy (2013) (44)
Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism. (1980) (44)
Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. (1986) (43)
Immediate decrease by hydrocortisone of the plasma half‐life of antipyrine (1973) (42)
Comparative Trial of Lisinopril and Nifedipine in Mild to Severe Essential Hypertension (1987) (42)
The in vitro metabolism of ethinyloestradiol, mestranol and levonorgestrel by human jejunal mucosa. (1981) (41)
Autoxidative formation of a chemically reactive intermediate from amodiaquine, a myelotoxin and hepatotoxin in man. (1987) (41)
The multiple dose pharmacokinetics of proguanil. (1993) (40)
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status. (1994) (40)
The effect of cotrimoxazole on oral contraceptive steroids in women. (1983) (39)
Pharmacogenetics: ethical problems and solutions (2004) (38)
Propranolol in the control of blood pressure: A dose‐response study (1980) (37)
A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. (1979) (36)
An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. (1979) (35)
A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. (2012) (35)
Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man. (1977) (35)
Drug-specific antibodies in patients receiving captopril. (1986) (32)
The effect of variations in urinary pH on the pharmacokinetics of diethylcarbamazine. (1981) (32)
A survey of the prevalence of penicillin-specific IgG, IgM and IgE antibodies detected by ELISA and defined by hapten inhibition, in patients with suspected penicillin allergy and in healthy volunteers. (1988) (32)
The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women. (1980) (32)
Benefit-Risk Appraisal of Medicines: A Systematic Approach to Decision-making (2010) (32)
The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. (1983) (31)
Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. (1985) (31)
Debate that "this house believes the essential drug concept hinders the effective deployment of drugs in developing countries". Introduction. (2003) (30)
The toxicity of amodiaquine and its principal metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units. (1990) (29)
Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography. (1984) (29)
Clinical implications of enzyme induction. (1971) (29)
First-pass effect of norethindrone in rabbits and rats. (1978) (29)
The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes. (1985) (28)
European Perspective on Risk Management and Drug Safety (2011) (28)
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: the future. (1994) (28)
The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. (1985) (28)
Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993) (1994) (28)
Advancing the Science of Medicines Regulation: The Role of the 21st‐Century Medicines Regulator (2012) (27)
WARFARIN AND DISTALGESIC INTERACTION (1976) (27)
Determination of arteether in blood plasma by high-performance liquid chromatography with ultraviolet detection after hydrolysis acid. (1989) (27)
Interactions between oral contraceptives and other drugs. (1979) (26)
Drug protein conjugates--VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates. (1983) (26)
Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes. (1989) (25)
High-performance liquid chromatographic analysis of amodiaquine in human plasma. (1985) (25)
The binding of the antimalarial arteether to human plasma proteins in‐vitro (1992) (24)
Cimetidine increases the action of warfarin in man [proceedings]. (1979) (24)
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. (1994) (23)
Thalidomide and its sequelae (2012) (23)
Trial of combination of guanethidine and oxprenolol in hypertension. (1976) (23)
Effect of malaria infection and endotoxin-induced fever on phenacetin O-deethylation by rat liver microsomes. (1993) (22)
HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. (1999) (22)
Currently important antimalarial drugs. (1987) (21)
Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities (2016) (21)
Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. (1994) (21)
Oral contraceptive steroid plasma concentrations in smokers and non-smokers. (1981) (21)
Evolution of regulatory frameworks (2010) (21)
Effect of dose size on amodiaquine pharmacokinetics after oral administration (2004) (21)
Enantiomers of warfarin and phenobarbital. (1976) (21)
Expediting Patients' Access to Medicines by Improving the Predictability of Drug Development and the Regulatory Approval Process (2010) (20)
Adverse drug reactions: a hospital pharmacy-based reporting scheme. (1989) (20)
Clinical significance of interactions with antifungal agents. (1992) (20)
The effect of oral contraceptive steroids and enzyme inducing drugs on sex hormone binding globulin capacity in women [proceedings]. (1980) (19)
The chemotherapy of onchocerciasis VII. The effect of prednisone on the Mazzotti reaction. (1982) (19)
Risk Sharing and Payment by Results (2008) (19)
FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines (2017) (19)
Rate of onset of hypotensive effect of oral labetalol. (1979) (19)
Interaction between warfarin and propranolol. (1984) (19)
Angiotensin converting enzyme inhibitors and quality of life. (1991) (19)
Clinical pharmacology and malaria. (1997) (18)
Regulatory Challenges, Reimbursement, and Risk–Benefit Assessment (2010) (18)
The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects (2004) (18)
The effects of indomethacin and naproxen on zidovudine pharmacokinetics. (1993) (18)
Drug interactions with oral contraceptive steroids. (1980) (18)
A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria (2004) (18)
The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. (1987) (17)
Monitoring the safety of licensed medicines (2005) (17)
Enzyme induction in humans. Clinical aspects--an overview. (1987) (17)
Increased glucuronidation of bilirubin in man and rat by administration of antipyrine (phenazone). (1974) (17)
New Drugs: Angiotensin converting enzyme inhibitors (1988) (16)
Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function. (1987) (15)
Drug-protein conjugates--IV. The effect of acute renal failure on the disposition of [14C]captopril in the rat. (1983) (15)
Inhibition of Dapsone‐induced Methaemoglobinaemia in the Rat Isolated Perfused Liver (1990) (15)
Risks and benefits of prophylactic antimalarial drugs. (1989) (15)
The chemotherapy of onchocerciasis IX. The effect of prednisone plus cyproheptadine on the Mazzotti reaction. (1982) (15)
A clinical pharmacologist's view of drug toxicity. (2003) (15)
Lisinopril in essential hypertension: a six month comparative study with nifedipine. (1987) (15)
Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. (1979) (14)
Review of yellow cards (1986): report to the Committee on the Safety of Medicines. (1988) (14)
Age-related effects of angiotensin converting enzyme inhibitors. (1988) (14)
The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis. (1986) (14)
Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation. (2019) (14)
Medicines Regulation and Health Technology Assessment (2010) (14)
Medicines regulation and the pharmaceutical industry (2005) (13)
Failure of antacids to alter the pharmacokinetics of phenytoin. (1978) (13)
Clinical review Fortnightly review Adverse drug reactions (1998) (13)
Lack of effect of highly purified subunit influenza vaccination on theophylline metabolism. (1985) (13)
Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women. (1988) (13)
Precision medicine and the changing role of regulatory agencies (2016) (12)
Plasma Xa inhibitory activities and plasma concentrations of norgestrel and ethinyloestradiol in women on oral contraceptive steroids. (1979) (12)
Regulatory Review: How Do Agencies Ensure the Quality of Decision Making? (2013) (12)
Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives. (2011) (12)
The chemotherapy of onchocerciasis VI. The effect of indomethacin and cyproheptadine on the Mazzotti reaction. (1982) (12)
A Trial of the Combination of Guanethidine and Oxprenolol in Hypertension (1974) (12)
Mechanisms of action of the anticoagulants warfarin, 2-chloro-3-phytylnaphthoquinone (Cl-K), acenocoumarol, brodifacoum and difenacoum in the rabbit [proceedings]. (1978) (12)
The future of clinical pharmacology in the UK (2006) (12)
Inhibition of dapsone-induced methaemoglobinaemia in the rat. (1990) (12)
The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. (1985) (11)
The disposition of pyrimethamine in the isolated perfused rat liver. (1985) (11)
Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria. (1990) (11)
Impact of Brexit on UK and EU Drug Regulation and Patient Access (2018) (11)
Determination of suramin in plasma by high-performance liquid chromatography. (1985) (11)
Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine. (1984) (11)
The Challenges of Orphan Drugs and Orphan Diseases: Real and Imagined (2012) (11)
The pharmacokinetics of oestrone sulphate in the rat. (1981) (11)
The effect of phenobarbitone-induction on vitamin D metabolism. (1972) (11)
William Withering's legacy--for the good of the patient. (2006) (11)
Labetalol in essential hypertension. (1982) (10)
Sex-dependent sensitivity to dapsone-induced methaemoglobinaemia in the rat. (1990) (10)
Advances in regulatory science at the Food and Drug Administration. (2013) (10)
Identification and quantification of diethylcarbamazine and diethylcarbamazine N-oxide in rat urine. (1981) (10)
Influence of environmental chemicals on drug therapy in humans: studies with contraceptive steroids. (1980) (9)
The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man. (1982) (9)
Drug Interactions with Warfarin (1983) (9)
Studies on the enzymatic cleavage of norethisterone oenanthate. (1981) (9)
Drug interactions with oral contraceptives (1978) (9)
Factors related to drug approvals: predictors of outcome? (2017) (9)
New horizons in pharmaceutical regulation (2012) (9)
The biliary and urinary metabolites of [3H]17 alpha-ethynylestradiol in women. (1983) (9)
The effect of diflunisal on the steady state pharmacodynamics and pharmacokinetics of warfarin [proceedings]. (1980) (9)
The pharmacokinetics of (+)- and (-)-primaquine in the isolated perfused rat liver preparation. (1987) (8)
Pharmacology of drugs for HIV (2001) (8)
Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed. (1994) (8)
Postgraduate education in therapeutics: experience in Merseyside. (1978) (8)
Clinical Pharmacology in the United Kingdom--a view for the 1990s. (1991) (8)
NATIONAL ADVERSE DRUG REACTION REPORTING—A SILVER JUBILEE (1989) (8)
Plasma urea in hypertensive patients. (1976) (8)
For the good of the patient: risks and benefits of medicines (2003) (8)
A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection - The Quattro Trial (1999) (7)
Early Access to New Medicines (2008) (7)
The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration. (1986) (7)
After thalidomide - do we have the right balance between public health and intellectual property. (2015) (7)
Development and delivery of clinical pharmacology in regulatory agencies. (2012) (7)
Assessment of new drugs: a clinical pharmacologist's view. (1980) (7)
Recent Advances: Clinical pharmacology and therapeutics (1995) (7)
Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications. (2015) (7)
The chemotherapy of onchocerciasis. XIV. Studies with mebendazole citrate. (1990) (7)
Patient opinions and preferences in drug development and regulatory decision making. (2011) (7)
Clinical pharmacology looks at tropical medicine. (1987) (7)
The Culyer report (1994) (7)
Ethynylestradiol and norethindrone metabolism by everted sacs of rat ileum. (1978) (7)
Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients. (1993) (6)
The dose-dependent effect of warfarin on vitamin K1 metabolism and clotting factor synthesis in the rabbit. (1980) (6)
Inhibition of estrogen 2-hydroxylase. (1986) (6)
The enzyme inducing effect of rifampicin in the rhesus monkey and its lack of interaction with oral contraceptive steroids. (1982) (6)
The in vitro metabolism of ethinyloestradiol, levonorgestrel and mestranol by human jejunal mucosa [proceedings]. (1980) (6)
Efficacy and Adverse Effects of Captopril in Severe Refractory Hypertension (1981) (6)
Vasodilators for heart failure (1982) (6)
The burden of adverse drug events. (2015) (6)
Action of clonidine on centrally evoked salivation in anaesthetized cats. (1979) (6)
Angiotensin converting enzyme inhibitors. (1988) (6)
Pharmacoeconomics Comes of Age? (2008) (5)
Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis. (1993) (5)
Contribution of the liver to overall elimination of propranolol (1976) (5)
Regulatory divergence (2011) (5)
The UK's NHS and pharma: need for more clinical pharmacologists (2009) (5)
Studies of metrifonate in onchocerciasis. (2009) (5)
Therapeutics and drug development (1997) (5)
Cardiovascular and respiratory disease therapy: edited by J. C. Petrie, Elsevier/North-Holland Biomedical Press, 1980. £48.25/Dfl 99.00 (ix + 243 pages) ISBN 0 444 80233 9 (1982) (5)
A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways. (2018) (5)
The future challenges (2004) (5)
Comparative efficacy of lisinopril and nifedipine retard in essential hypertension: a double-blind, placebo-controlled trial. (1987) (5)
25 Years of the Committee on Safety of Medicines (1990) (4)
Screening methods for measuring liver microsomal enzyme induction by drugs. (1969) (4)
Clinical pharmacokinetics of drugs against onchocerciasis. (1990) (4)
Regulatory Frameworks in Times of Uncertainty (2018) (4)
Drug treatment of onchocerciasis. (1988) (4)
Zidovudine therapy in HIV infection: which patients should be treated and when. (1995) (4)
Observations of HIV-1 Genotypic Drug Resistance in a Trial of Four Reverse Transcriptase Inhibitors (Quattro Trial) (2002) (4)
Induction of drug metabolizing enzymes in man. (1970) (4)
Increased Rate of Metabolism of Vitamin D 3 in Phenobarbitone-Induced Rats (1972) (4)
Clinical pharmacology of oral contraceptive steroids: drug interactions (1980) (4)
Antipyrine Half-life and Drug Elimination (1980) (4)
High-performance liquid chromatographic method for the determination of pyrimethamine and its 3-N-oxide metabolite in biological fluids (1998) (4)
Interindividual Variation and Drug Interactions with Hormonal Steroid Contraceptives (2012) (4)
Severe orthostatic hypotension associated with carcinoma of the bronchus. (1979) (3)
A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways (2020) (3)
Drug metabolism and tropical disease. (1984) (3)
Adverse effects of captopril in hospital outpatients with hypertension. (1990) (3)
RIGHT VENTRICULAR PRESSURE FLOW RELATIONSHIPS AND INTRACARDIAC VENTURI EFFECTS IN FALLOT'S TETRALOGY (1964) (3)
Plasma disposition ofvitamin K1inrelation toanticoagulant poisoning (1984) (3)
Post‐marketing Strategies for Medicines (2008) (3)
Psilocybin: promising results in double-blind trials require confirmation by real-world evidence (2016) (3)
Thromboembolism in pregnancy. (1979) (3)
IMPACT OF DRUG MONOXYGENASES IN CLINICAL PHARMACOLOGY (1977) (3)
The detection of amodiaquine in blood after oral administration. (1986) (3)
Accelerated approval of medicines: fit for purpose? (2018) (3)
Approaches to pharmacoeconomic analysis (2004) (3)
Drug interactions during metabolism in the liver (2004) (2)
Different vasodilating mechanisms--different peripheral effects? (1992) (2)
Towards a prevention model of health care (2013) (2)
The pharmacokinetics of norethisterone in the rabbit and rat after systemic and oral administration: effect of phenobarbitone [proceedings]. (1977) (2)
Science, medicine and clinical pharmacology. The Lilly Lecture 1994. (1995) (2)
Commentary on ‘Transparency and Trust in the European Pharmaceutical Sector’ (2016) (2)
The changing scene of the regulation of medicines in the UK. Paper from The Use of Medicines: Regulation & Clinical Pharmacology in the 21st Century Symposium - December 2003. (2004) (2)
Chronic Effects of Captopril, Atenolol, Pindolol and Labetalol in Hypertension Complicated by Intermittent Claudication (1987) (2)
The interaction of antibiotics with ethinyloestradiol in the rat and rabbit [proceedings]. (1980) (2)
A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance (2005) (2)
THE DISPOSITION OF A SINGLE INFUSION OF CHLOROQUINE IN PATIENTS WITH VIVAX MALARIA (1986) (2)
Biliary excretion of synthetic sex steroids in heterozygous and homozygous Gunn rats. (1978) (2)
Poor medication adherence in clinical trials: consequences and solutions (2017) (2)
Current controversies in the treatment of hypertension. (1988) (2)
Hepatic clearance of propranolol in dogs. (1973) (2)
Interactions ofBenzodiazepines withWarfarin (1972) (2)
Regulatory Consequences of “Brexit” for the Development of Medicinal Products (2017) (2)
High-performance liquid chromatographic method for the determination of amopyroquine in biological fluids. (1987) (2)
Angiotensin converting enzyme inhibition in clinical practice. Re-examination of step care: choice of first drug. (1985) (1)
Clinical pharmacology in the 1990s: a personal perspective. (1993) (1)
Ageing, Serotonin and Ketanserin (2012) (1)
High-performance liquid chromatographic method for the determination of pyrimethamine and its 3-N-oxide metabolite in biological fluids. (1984) (1)
Modelling in health economics (2004) (1)
Drugs and intravenous fluids. (1984) (1)
Malaria infection and endotoxininduced fever decrease phenacetin O-deethylation by rat liver microsomes (1993) (1)
Optimal dose identification : proceedings of the Esteve Foundation Symposium IX, Lloret de Mar (Girona), Spain, 4-7 October 2000 (2001) (1)
Transcutaneous oxygen tension during exercise in patients with claudication (1986) (1)
HIV adverse drug reaction (ADR) reporting scheme (1998) (1)
Inhibition of tolbutamide metabolism by antimalarial drugs. (1988) (1)
Digitalis and other cardiac glycosides. (1979) (1)
[Oral contraceptive steroid plasma concentrations in smokers and non-smokers (author's transl)]. (1982) (1)
Trial ofcombination ofguanethidine andoxprenolol inhypertension (1976) (1)
Urinary steroid glucuronides in women taking oral contraceptives. (1983) (1)
Reporting adverse drug reactions in HIV infection. (1997) (1)
Induction of drug metabolizing enzymes in man and rat by dichloralphenazone. (1969) (1)
Pharmacokinetics ofprimaquine inman. I.Studies oftheabsolute bioavailability andeffects ofdosesize (1985) (1)
Drugs in the Management of Heart Disease (1985) (1)
Concern about records of fibrosing colonopathy study (2001) (1)
806 – VITAMIN K AND VARIATION IN RESPONSE TO ORAL ANTICOAGULANTS (1978) (1)
The immunogenicity and disposition of benzylpenicillin and its degradation products in the rat (1987) (1)
Clinical pharmacology and drug regulation. (1999) (1)
Angiotensin infusion test in hypertension. (1966) (1)
An Introduction to Mechanisms in Pharmacology and Therapeutics (1976) (1)
New-drug assessment in man: a clinical pharmacologist’s view (1981) (1)
242. Plasma ethinyloestradiol concentration in rabbits and women (1978) (1)
Antiretroviral drug trials. (1997) (1)
Dose - response relationship between warfarin and the metabolism of phylloquinone (vitamin K1) in man. (1976) (1)
Clinical pharmacology teaching, training and career development. (1986) (1)
Who needs clinical pharmacology? (1984) (0)
2017 Reviewer Acknowledgment (2018) (0)
Pharmacodynamics and drug development: Edited by Neal R. Cutler, John R. Sramek and Prem K. Narong, Wiley, 1994. £65.00 (xv + 491 pages) ISBN 0 471 950 521 (1995) (0)
The effect of cigarette smoking on plasma concentrations of oral contraceptive steroids. (1981) (0)
547 – TNTERINDIVIDUAL DIFFERENCES IN DRUG RESPONSE - STUDIES WITH INDOMETHACIN AND ORAL CONTRACEPTIVE STEROIDS (1978) (0)
The effect of variable drug metabolism on the pharmacokinetics of proguanil in man (1990) (0)
Ron Mann: Pharmacoepidemiologist, 1928-2013. (2014) (0)
Antihypertensive Drugs Today: Cardiovascular Drugs, vol 4. (1980) (0)
Calcium channel antagonists andcyclosporine metabolism: invitro studies withhumanliver microsomes (1989) (0)
In memoriam: Ronald D. Mann, MD, FRCP, FRCGP, FFPM, FISPE, Professor Emeritus, Honorary Lifetime ISPE Fellow, 1928–2013 (2014) (0)
Forthcoming meeting (1983) (0)
The pharmacokinetics of tritiated ethinylestradiol in the rabbit (1978) (0)
Generic substitution (1983) (0)
Book Review: Advances in Drug Research, vol 11 (1978) (0)
Adverse drug reaction of the month--a new series. (1997) (0)
Proceedings: Alterations in the response to warfarin. (1974) (0)
Factors Leading to Dependence on Hypnotic Drugs (0)
1178 – FIRST PASS EFFECT OF NORETHISTERONE IN RATS (1978) (0)
Election of Faculty Members and Fellows (2012) (0)
INHIBITION OF THEOPHYLLINE METABOLISM BY INTERFERON (1987) (0)
The 2006 Adrian Salter Lecture (2007) (0)
Vasodilators in Heart-failure (1978) (0)
A farewell to Alasdair. (2003) (0)
Pharmacokinetics and "potency" of contraceptive steroids [letter] (1984) (0)
Prof. John Urquhart. (2016) (0)
Theeffect ofmoderate urine alkalinisation onlowdose diethylcarbamazine therapy inpatients withonchocerciasis (1986) (0)
Clinical pharmacology in the 1990s: a personal perspective (1993) (0)
Reproducibility and Changes in Ejection Fraction (EF) Measured by Transthoracic Electrical Bioimpedance (TEB) in Healthy Subjects (1992) (0)
Clinical Pharmacology (1984) (0)
THE EFFECTOFRENAL DISEASEON THE PHARMACOKINETICS OFDIETHYLCARBAMAZINE INMAN (1982) (0)
UK HIV Adverse Drug Reactions Reporting Scheme (1998) (0)
Vitamin K1metabolism inrelation topharmacodynamic response inanticoagulated patients (1985) (0)
Interaction of ethinyloestradiol with ascorbic acid (1981) (0)
Interindividual Differences in Drug Response. Studies with Indomethacin and Oral Contraceptive Steroids (1979) (0)
Obituary Professor Jim Petrie (2001) (0)
Invitro metabolism ofthebiguanide antimalarials inhuman liver microsomes: evidence foraroleofthemephenytoin hydroxylase (P450 MP)enzyme (1990) (0)
Clinical Pharmacology (1976) (0)
Dose-dependent enzyme induction. (1973) (0)
Handbook for drugo for tropical parasitic infections: Lars L. Gustafsson, Björn Beerman and. Yakoub Aden Abdi, Taylor and Francis, 1987. £24.00 hbk, £11.00 pbk (viii + 151 pages) ISBN 0 85066 404 7 (1988) (0)
Some Christmas Books: A Christmas present for oneself (1975) (0)
The pharmacokinetics of ethinyloestradiol in women [proceedings]. (1979) (0)
Adverse effects ofcaptopril inhospital outpatients with hypertension (1990) (0)
Pharmacology at a glance. Second edition (1993) (0)
Interaction between warfarin and propranolol. (1984) (0)
II.Clinical pharmacology andtherapeutics inundergraduate medical education intheUK:thefuture (1994) (0)
How European Regulators View Foreign Data in the Approval Process (2008) (0)
[Drugs and fluids for the intravenous route]. (1985) (0)
POSSIBLE HAZARDS OF SEX HORMONE REPLACEMENT THERAPY (1979) (0)
Nelfinavir: A Viewpoint (1997) (0)
Theuseofcimetidine toreduce dapsone-dependent methaemoglobinaemia indermatitis herpetiformis patients (1992) (0)
EDITORIAL INDEPENDENCE OF PRESCRIBERS' JOURNAL (1979) (0)
Pharmacokinetics ofprimaquine inman II.Comparison ofacutevschronic dosage inThaisubjects (1985) (0)
Simultaneous onset of malignant hypertension in identical twins. (1973) (0)
Drugs and intravenous fluids. (1984) (0)
The interaction of antibiotics with synthetic steroids in the rat [proceedings]. (1978) (0)
2080 – RIFAMPICIN AND ORAL CONTRACEPTIVE STEROID INTERACTION (1978) (0)
Book Review: Antihypertensive Drugs Today (1980) (0)
Lecture notes on clinical pharmacology. Fourth edition (1993) (0)
STEREOCHEMICALASPECTSOF ITSMETABOLISM AND THE INTERACTIONWITH PHENYLBUTAZONE (1974) (0)
[Modification of the action of drugs by inhibition of their metabolism]. (1979) (0)
Comparison of Ejection Fraction (EF) Measured by Transthoracic Electrical Bioimpedance (TEB) and Multi-Gated Radionuclide (MUGA) Scanning in Patients (1992) (0)
The pharmacokinetics of norethisterone during single and multiple dosing in women and changes caused by rifampicin. (Abstract only) (1977) (0)
ZIDOVUDINE PHOSPHORYLATION IN HIV PATIENTS AND SERONEGATIVE VOLUNTEERS (1994) (0)
Clinicians' attitudes to reporting adverse drug reactions (2000) (0)
PHARMACOKINETICS AND "POTENCY" OF CONTRACEPTIVE STEROIDS (1984) (0)
PHAEMACOKINETICS OF ZIDOVUDINE AND DIDEOXYINOSINE ALONE AND IN COMBINATION IN CHILDREN WITH HIV INFECTION (1994) (0)
Rational therapeutics: A clinical pharmacological guide for the health professional (1991) (0)
1483 – A NOVEL METHOD OF STUDYING DRUG INTERACTIONS WITH ORAL ANTICOAGULANTS; CLOFIBRATE AND WARFARIN (1978) (0)
Response to “Medicines Shortages in the United Kingdom” (2019) (0)
Thepharmacokinetics andactivation ofproguanil inman: consequences ofvariability indrugmetabolism (1990) (0)
The reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat [proceedings]. (1978) (0)
THEEFFECTSOFAMPICILLINON ORAL CONTRACEPTIVE STEROIDSINWOMEN (1982) (0)
Society of Pharmaceutical Medicine (2012) (0)
An audience with... Sir Alasdair Breckenridge. Interview by Joanna Owens. (2006) (0)
Therelationship between inhibition ofvitamin K12,3-epoxide reductase andreduction ofclotting factor activity withwarfarin (1988) (0)
Theeffects ofindomethacin andnaproxen on zidovudine pharmacokinetics (1993) (0)
Ejection fraction by transthoracic electrical bioimpedance : reproducibility and comparison with multi-gated radionuclide scan (1993) (0)
Glutathione Deficiency in Hiv-Infected Patients: A True or Technical Deficiency? (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alasdair Muir Breckenridge?

Alasdair Muir Breckenridge is affiliated with the following schools:

Alasdair Muir Breckenridge's Academic­Influence.com Rankings

Why Is Alasdair Muir Breckenridge Influential?

Alasdair Muir Breckenridge's Published Works

Published Works

What Schools Are Affiliated With Alasdair Muir Breckenridge?

Alasdair Muir Breckenridge's AcademicInfluence.com Rankings